Patents by Inventor Hae-Young Yong

Hae-Young Yong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240092913
    Abstract: The present disclosure relates to an isolated anti-FcRN antibody, which is an antibody binding to FcRN (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmunre diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.
    Type: Application
    Filed: November 17, 2023
    Publication date: March 21, 2024
    Applicant: HANALL BIOPHARMA CO., LTD.
    Inventors: Sung Wuk KIM, Seung Kook PARK, Jae Kap JEONG, Hyea Kyung AHN, Min Sun KIM, Eun Sun KIM, Hae-Young YONG, Dongok SHIN, Yeon Jung SONG, Tae Hyoung YOO
  • Publication number: 20230235063
    Abstract: The present disclosure relates to an isolated anti-FcRN antibody, which is an antibody binding to FcRN (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.
    Type: Application
    Filed: February 21, 2023
    Publication date: July 27, 2023
    Applicant: Hanall Biopharma Co., Ltd.
    Inventors: Sung Wuk Kim, Seung Kook Park, Jae Kap Jeong, Hyea Kyung Ahn, Min Sun Kim, Eun Sun Kim, Hae-Young Yong, Dongok Shin, Yeon Jung Song, Tae Hyoung Yoo
  • Patent number: 11613578
    Abstract: The present disclosure relates to an isolated anti-FcRn antibody, which is an antibody binding to FcRn (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: March 28, 2023
    Assignee: HANALL BIOPHARMA CO., LTD.
    Inventors: Sung Wuk Kim, Seung Kook Park, Jae Kap Jeong, Hyea Kyung Ahn, Min Sun Kim, Eun Sun Kim, Hae-Young Yong, Dongok Shin, Yeon Jung Song, Tae Hyoung Yoo
  • Publication number: 20200109201
    Abstract: The present disclosure relates to an isolated anti-FcRn antibody, which is an antibody binding to FcRn (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.
    Type: Application
    Filed: December 11, 2019
    Publication date: April 9, 2020
    Inventors: Sung Wuk KIM, Seung Kook PARK, Jae Kap JEONG, Hyea Kyung AHN, Min Sun KIM, Eun Sun KIM, Hae-Young YONG, Dongok SHIN, Yeon Jung SONG, Tae Hyoung YOO
  • Patent number: 10544226
    Abstract: The present disclosure relates to an isolated anti-FcRn antibody, which is an antibody binding to FcRn (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: January 28, 2020
    Assignee: HANALL BIOPHARMA CO., LTD.
    Inventors: Sung Wuk Kim, Seung Kook Park, Jae Kap Jeong, Hyea Kyung Ahn, Min Sun Kim, Eun Sun Kim, Hae-Young Yong, Dongok Shin, Yeon Jung Song, Tae Hyoung Yoo
  • Patent number: 10336825
    Abstract: The present disclosure relates to an isolated anti-FcRn antibody, which is an antibody binding to FcRn (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: July 2, 2019
    Assignee: HANALL BIOPHARMA CO., LTD.
    Inventors: Sung Wuk Kim, Seung Kook Park, Jae Kap Jeong, Hyea Kyung Ahn, Min Sun Kim, Eun Sun Kim, Hae-Young Yong, Dongok Shin, Yeon Jung Song, Tae Hyoung Yoo
  • Publication number: 20190135917
    Abstract: The present disclosure relates to an isolated anti-FcRn antibody, which is an antibody binding to FcRn (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.
    Type: Application
    Filed: January 15, 2019
    Publication date: May 9, 2019
    Inventors: Sung Wuk KIM, Seung Kook PARK, Jae Kap JEONG, Hyea Kyung AHN, Min Sun KIM, Eun Sun KIM, Hae-Young YONG, Dongok SHIN, Yeon Jung SONG, Tae Hyoung YOO
  • Patent number: 10280207
    Abstract: The present invention relates to a human antibody specific for FcRn that is a receptor with a high affinity for IgG, a production method thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune disease using the same. The FcRn-specific antibody according to the present invention can bind to FcRn non-competitively with IgG or the like to reduce serum auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: May 7, 2019
    Assignee: HANALL BIOPHARMA CO., LTD.
    Inventors: Sung Wuk Kim, Seung Kook Park, Jae Kap Jeong, Min Sun Kim, Eun Sun Kim, Jeong Haing Heo, Yeon Jung Song, Hae-Young Yong, Dongok Shin
  • Publication number: 20170210805
    Abstract: The present disclosure relates to an isolated anti-FcRn antibody, which is an antibody binding to FcRn (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.
    Type: Application
    Filed: April 5, 2017
    Publication date: July 27, 2017
    Inventors: Sung Wuk Kim, Seung Kook Park, Jae Kap Jeong, Hyea Kyung Ahn, Min Sun Kim, Eun Sun Kim, Hae-Young Yong, Dongok Shin, Yeon Jung Song, Tae Hyoung Yoo
  • Publication number: 20170210801
    Abstract: The present disclosure relates to an isolated anti-FcRn antibody, which is an antibody binding to FcRn (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.
    Type: Application
    Filed: April 30, 2015
    Publication date: July 27, 2017
    Inventors: Sung Wuk Kim, Seung Kook Park, Jae Kap Jeong, Hyea Kyung Ahn, Min Sun Kim, Eun Sun Kim, Hae-Young Yong, Dongok Shin, Yeon Jung Song, Tae Hyoung Yoo
  • Publication number: 20160137713
    Abstract: The present invention relates to a human antibody specific for FcRn that is a receptor with a high affinity for IgG, a production method thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune disease using the same. The FcRn-specific antibody according to the present invention can bind to FcRn non-competitively with IgG or the like to reduce serum auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.
    Type: Application
    Filed: June 20, 2014
    Publication date: May 19, 2016
    Inventors: Sung Wuk Kim, Seung Kook Park, Jae Kap Jeong, Min Sun Kim, Eun Sun Kim, Jeong Haing Heo, Yeon Jung Song, Hae-Young Yong, Dongok Shin